FindTrial
Sign In

Therapeutic benefits of black seed oil in patients with COPD

Therapeutic effects of black seed oil supplementation in patients with chronic obstructive pulmonary disease

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/04/024927
Enrollment
100
Registered
2020-04-30
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J44- Other chronic obstructive pulmonary disease

Interventions

Intervention1: inhaled corticosteroids with long-acting β2-agonist Black seed oil as an adjunct therapy for COPD patients: treatment for 3 months 1. dose of 50 micrograms of salmeterol (as salmeterol

Sponsors

Reda Abdel Latif Ibrahem
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients of 40â??66 age groups, irrespective of gender; (2) Stable mild to moderate COPD patients who had given written informed consent to participate in the study; (3) Ambulatory and cooperative.

Exclusion criteria

Exclusion criteria: 1) Patients below the age of 40 years and above 66 years; (2) Patients with any respiratory tract infection during the past 4 weeks; (3) Patients with chronic or acute diseases known to be associated with elevated oxidative stress (liver diseases, renal diseases, heart diseases, thyroid disorders, coagulation disorders, hematologic problems, diabetes mellitus, acute respiratory distress syndrome, any CNS disorder etc.; (4) patients who were hypersensitive to any of the conventional COPD drugs; (5) Patients have taken antioxidants and vitamins supplements in the last 4 weeks; (6) pregnant/ lactating females; (7) severe and very severe cases were not enrolled in this study.

Design outcomes

Primary

MeasureTime frame
pulmonary functionsincluding FVC%, FEV1% and their ratios (FEV1/FVC) %, PEF%, and FEF 25-75% values were measured on 0 day and after 12 weeks.Timepoint: base line and 12 weeks—

Secondary

MeasureTime frame
1. oxidative stress markers [(Thiobarbituric acid reactive-substances (TBARS) and Protein carbonyl (PC) content)] 2. antioxidants markers [(Catalase (CAT), Glutathione peroxidase (GPx), Superoxide dismutase (SOD), Reduced glutathione (GSH), Vitamin C, and vitamin E)] 3. inflammatory marker [(Tumor necrosis factor-alpha (TNF-α) and Interleukin-6, (IL-6)]Timepoint: at base line and 12 weeks—

Countries

Egypt

Contacts

Public ContactReda Abdel Latif Ibrahem

zagazig university hospital

mmahmood41@yahoo.com009647811244735

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026